ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-010 for Cystic Fibrosis at Two Upcoming Scientific Conferences

LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that the company will present abstracts with pre-clinical data for its cystic fibrosis program at the 29th Annual North American Cystic Fibrosis Conference (NACFC) in Phoenix, Arizona, October 8 – 10, 2015 and the 11th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Leiden, The Netherlands, October 11 – 14, 2015.

NACFC

'QR-010 Treatment for Cystic Fibrosis; Assessing the Airway-Mucus Barrier in Delivery', poster #214, will be presented October 8th, 11:50 – 1:50pm MT and October 9th, 7:30 – 8:45am MT. The poster will also be highlighted in the poster workshop session, 'New Therapies & Outcomes,' on October 10th, 10:30 – 12:15pm MT. The abstract is available in a special issue of Pediatric Pulmonology.

Investor and analyst event at NACFC

On October 8th at 6:30pm MT, ProQR management invites investors and analysts to an event with Brian Button, PhD, Assistant Professor of Medicine at University of North Carolina at Chapel Hill to further discuss the presented pre-clinical data. For more information or to RSVP, please contact Sariette Witte at ir@proqr.com.

OTS

The abstract titled: 'QR-010 penetrates the mucus barrier in vitro and in vivo' will be presented in a poster during the conference. The abstract will be available on the OTS website prior to the conference.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.

ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494
gschweitzer@macbiocom.com

You might like this

  • About ProQR Therapeutics

    ProQR was founded by Daniel de Boer with a mission to help people living with rare genetic diseases. This remains the main focus of our company today.

    Daniel de Boer wearing a blue suit stands with arm crossed in a laboratory setting.

  • Axiomer technology - RNA base editing

    A new way to use RNA oligonucleotides to alter RNA, discovered by ProQR. The Axiomer® technology enables the editing of specific single nucleotides in RNA using the cells own editing machinery.

    Axiomer RNA editing platform technology

  • Our science

    Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments for people with severe rare and common diseases.

    ProQR laboratory technicians